Tags

Type your tag names separated by a space and hit enter

Buprenorphine transdermal system and quality of life in opioid-experienced patients with chronic low back pain.
Expert Opin Pharmacother. 2013 Feb; 14(3):269-77.EO

Abstract

OBJECTIVES

To evaluate the impact of 12 weeks of treatment with Butrans® (buprenorphine) transdermal system (BTDS) on the health-related quality of life (HRQoL) for patients with chronic low back pain (CLBP), and the maintenance of effects over 52 weeks.

RESEARCH DESIGN AND METHODS

A multicenter, enriched, double-blind (DB), randomized trial comparing BTDS 20 μg/h (BTDS 20) against 5 μg/h (BTDS 5) for treatment of opioid-experienced patients with moderate-to-severe CLBP, including a 52-week open-label (OL) extension phase.

MAIN OUTCOME MEASURES

QoL was measured with the SF-36v2 survey before and after an OL run-in period with BTDS 20, three times during the DB phase, and seven times over the extension phase. This post hoc analysis tested for SF-36v2 score differences between treatment groups during the DB phase and maintenance of effects over the extension phase.

RESULTS

At 12 weeks, BTDS 20 produced larger improvements than BTDS 5 in role limitations due to physical health, bodily pain and overall physical QoL (p < 0.01). Treatment group differences in overall physical QoL were sustained throughout the DB phase. Quality-of-life improvements associated with BTDS 20 persisted through the extension phase.

CONCLUSIONS

These data suggest that opioid-experienced moderate-to-severe CLBP patients receiving BTDS 20 exhibited better QoL than patients receiving BTDS 5.

Authors+Show Affiliations

QualityMetric, Inc./OptumInsight, 24 Albion Road, Building 400, Lincoln, RI 02865, USA. kmiller@qualitymetric.comNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info available

Pub Type(s)

Comparative Study
Journal Article
Multicenter Study
Randomized Controlled Trial
Research Support, Non-U.S. Gov't

Language

eng

PubMed ID

23374027

Citation

Miller, Kate, et al. "Buprenorphine Transdermal System and Quality of Life in Opioid-experienced Patients With Chronic Low Back Pain." Expert Opinion On Pharmacotherapy, vol. 14, no. 3, 2013, pp. 269-77.
Miller K, Yarlas A, Wen W, et al. Buprenorphine transdermal system and quality of life in opioid-experienced patients with chronic low back pain. Expert Opin Pharmacother. 2013;14(3):269-77.
Miller, K., Yarlas, A., Wen, W., Dain, B., Lynch, S. Y., Brennan, M. J., & Ripa, S. R. (2013). Buprenorphine transdermal system and quality of life in opioid-experienced patients with chronic low back pain. Expert Opinion On Pharmacotherapy, 14(3), 269-77. https://doi.org/10.1517/14656566.2013.767331
Miller K, et al. Buprenorphine Transdermal System and Quality of Life in Opioid-experienced Patients With Chronic Low Back Pain. Expert Opin Pharmacother. 2013;14(3):269-77. PubMed PMID: 23374027.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - Buprenorphine transdermal system and quality of life in opioid-experienced patients with chronic low back pain. AU - Miller,Kate, AU - Yarlas,Aaron, AU - Wen,Warren, AU - Dain,Bradley, AU - Lynch,Shau Yu, AU - Brennan,Michael J, AU - Ripa,Steven R, PY - 2013/2/5/entrez PY - 2013/2/5/pubmed PY - 2013/7/23/medline SP - 269 EP - 77 JF - Expert opinion on pharmacotherapy JO - Expert Opin Pharmacother VL - 14 IS - 3 N2 - OBJECTIVES: To evaluate the impact of 12 weeks of treatment with Butrans® (buprenorphine) transdermal system (BTDS) on the health-related quality of life (HRQoL) for patients with chronic low back pain (CLBP), and the maintenance of effects over 52 weeks. RESEARCH DESIGN AND METHODS: A multicenter, enriched, double-blind (DB), randomized trial comparing BTDS 20 μg/h (BTDS 20) against 5 μg/h (BTDS 5) for treatment of opioid-experienced patients with moderate-to-severe CLBP, including a 52-week open-label (OL) extension phase. MAIN OUTCOME MEASURES: QoL was measured with the SF-36v2 survey before and after an OL run-in period with BTDS 20, three times during the DB phase, and seven times over the extension phase. This post hoc analysis tested for SF-36v2 score differences between treatment groups during the DB phase and maintenance of effects over the extension phase. RESULTS: At 12 weeks, BTDS 20 produced larger improvements than BTDS 5 in role limitations due to physical health, bodily pain and overall physical QoL (p < 0.01). Treatment group differences in overall physical QoL were sustained throughout the DB phase. Quality-of-life improvements associated with BTDS 20 persisted through the extension phase. CONCLUSIONS: These data suggest that opioid-experienced moderate-to-severe CLBP patients receiving BTDS 20 exhibited better QoL than patients receiving BTDS 5. SN - 1744-7666 UR - https://www.unboundmedicine.com/medline/citation/23374027/Buprenorphine_transdermal_system_and_quality_of_life_in_opioid_experienced_patients_with_chronic_low_back_pain_ L2 - http://www.tandfonline.com/doi/full/10.1517/14656566.2013.767331 DB - PRIME DP - Unbound Medicine ER -